EUVIMEDEUVIMED entdecken
Open Access

Astragaloside IV enhances the sensitivity of breast cancer stem cells to paclitaxel by inhibiting stemness

Ping Huang, Huachao Li, Liping Ren, Haimei Xie, Liushan Chen, Yuqi Liang, Yuyu Hu, Heloisa Sobreiro Selistre-de-Araujo, Stergios Boussios, Sachin R Jhawar, Rutao Cui, Qian Zuo und 1 weitere

Translational Cancer Research · 2023-12 · 12 (12) · 3703-3717

DOI: 10.21037/tcr-23-1885 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Translational Cancer Research, 2023-12. Verfasst von Ping Huang und 12 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Traditional Chinese Medicine Syndrome, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou,…. Die Arbeit wurde bisher 11-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chemotherapy is one of the common treatments for breast cancer. The induction of cancer stem cells (CSCs) is an important reason for chemotherapy failure and breast cancer recurrence. Astragaloside IV (ASIV) is one of the effective components of the traditional Chinese medicine (TCM) Astragalus membranaceus, which can improve the sensitivity of various tumors to chemotherapy drugs. Here, we explored the sensitization effect of ASIV to chemotherapy drug paclitaxel (PTX) in breast cancer from the perspective of CSCs.

Methods

The study included both in vitro and in vivo experiments. CSCs from the breast cancer cell line MCF7 with stem cell characteristics were successfully induced in vitro. Cell viability and proliferation were detected using the Cell Counting Kit-8 (CCK-8) and colony formation assays, and flow cytometry and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) methods were performed to detect cell apoptosis. Stemness-related protein expression was determined by western blotting (WB) and immunohistochemistry (IHC). Body weight, histopathology, and visceral organ damage of mice were used to monitor drug toxicity.

Results

The expression of stemness markers including Sox2, Nanog, and ALDHA1 was stronger in MCF7-CSCs than in MCF7. PTX treatment inhibited the proliferation of tumor cells by promoting cell apoptosis, whereas the stemness of breast cancer stem cells (BCSCs) resisted the effects of PTX. ASIV decreased the stemness of BCSCs, increased the sensitivity of BCSCs to PTX, and synergistically promoted PTX-induced apoptosis of breast cancer cells. Our results showed that the total cell apoptosis rate increased by about 25% after adding ASIV compared with BCSCs treated with PTX alone. The in vivo experiments demonstrated that ASIV enhanced the ability of PTX to inhibit the growth of breast cancer. WB and IHC showed that ASIV reduced the stemness of CSCs.

Conclusions

In this study, the resistance of breast cancer to PTX was attributed to the existence of CSCs; ASIV weakened the resistance of MCF7-CSCs to PTX by significantly attenuating the hallmarks of breast cancer stemness and improved the efficacy of PTX.

Schlagwörter

Stichwörter der Autor:innen

Breast cancerastragaloside IV (ASIV)cancer stem cells (CSCs)chemotherapypaclitaxel (PTX)

Autor:innen und Institutionen

  • State Key Laboratory of Traditional Chinese Medicine Syndrome, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
  • Department of Breast, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China.
  • Guangdong Academy of Chinese Medicine, Guangzhou, China.
  • Biochemistry and Molecular Biology Laboratory, Department of Physiological Sciences, Universidade Federal de São Carlos (UFSCar), São Carlos, Brazil.
  • Department of Medical Oncology, Medway NHS Foundation Trust, Kent, UK.
  • Faculty of Life Sciences & Medicine, School of Cancer & Pharmaceutical Sciences, King's College London, London, UK.

Zitieren

APA

Huang, P., Li, H., Ren, L., Xie, H., Chen, L., Liang, Y., Hu, Y., Selistre-de-Araujo, H. S., Boussios, S., Jhawar, S. R., Cui, R., Zuo, Q., & Chen, Q. (2023). Astragaloside IV enhances the sensitivity of breast cancer stem cells to paclitaxel by inhibiting stemness. Translational Cancer Research, 12(12), 3703-3717. https://doi.org/10.21037/tcr-23-1885

Vancouver

Huang P, Li H, Ren L, Xie H, Chen L, Liang Y, et al. Astragaloside IV enhances the sensitivity of breast cancer stem cells to paclitaxel by inhibiting stemness. Translational Cancer Research. 2023;12(12):3703-3717. doi:10.21037/tcr-23-1885

BibTeX
@article{Huang2023,
  author = {Huang, Ping and Li, Huachao and Ren, Liping and Xie, Haimei and Chen, Liushan and Liang, Yuqi and Hu, Yuyu and Selistre-de-Araujo, Heloisa Sobreiro and Boussios, Stergios and Jhawar, Sachin R and Cui, Rutao and Zuo, Qian and Chen, Qianjun},
  title = {Astragaloside IV enhances the sensitivity of breast cancer stem cells to paclitaxel by inhibiting stemness},
  journal = {Translational Cancer Research},
  year = {2023},
  volume = {12},
  number = {12},
  pages = {3703--3717},
  doi = {10.21037/tcr-23-1885}
}
Kostenlos starten →